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Abstract
Background: Oligosaccharides containing a terminal Gal-a1,3-Gal moiety are collectively known as a-Gal epitopes.
a-Gal epitopes are integral components of several medical treatments under development, including flu and HIV
vaccines as well as cancer treatments. The difficulty associated with synthesizing the a-Gal epitope hinders the
development and application of these treatments due to the limited availability and high cost of the a-Gal
epitope. This work illustrates the development of a whole-cell biocatalyst for synthesizing the a-Gal epitope, Gal-
a1,3-Lac.
Results: Agrobacterium sp. ATCC 31749 was engineered to produce Gal-a1,3-Lac by the introduction of a UDP-
galactose 4’-epimerase:a1,3-galactosyltransferase fusion enzyme. The engineered Agrobacterium synthesized 0.4 g/L
of the a-Gal epitope. Additional metabolic engineering efforts addressed the factors limiting a-Gal epitope
production, namely the availability of the two substrates, lactose and UDP-glucose. Through expression of a lactose
permease, the intracellular lactose concentration increased by 60 to 110%, subsequently leading to an
improvement in Gal-a1,3-Lac production. Knockout of the curdlan synthase gene increased UDP-glucose availability
by eliminating the consumption of UDP-glucose for synthesis of the curdlan polysaccharide. With these additional
engineering efforts, the final engineered strain synthesized approximately 1 g/L of Gal-a1,3-Lac.
Conclusions: The Agrobacterium biocatalyst developed in this work synthesizes gram-scale quantities of a-Gal
epitope and does not require expensive cofactors or permeabilization, making it a useful biocatalyst for industrial
production of the a-Gal epitope. Furthermore, the engineered Agrobacterium, with increased lactose uptake and
improved UDP-glucose availability, is a promising host for the production of other medically-relevant
oligosaccharides.
Background
a-Gal epitopes are oligosaccharides containing terminal
Gal-a1,3-Gal residues. In nature, three main a-Gal epi-
topes are produced: two trisaccharides (Gal-a1,3-Gal-
b1,4-GlcNAc and Gal-a1,3-Lac) and a pentasaccharide
(Gal-a1,3-Gal-b1,4-GlcNAc-b1,3-Gal-b1,4-Glc). These
epitopes are components of glycolipids and glycopro-
teins displayed on the cell surface of non-primate mam-
mals and New World monkeys via expression of an
a1,3-galactosyltransferase (a1,3-GalT). The a1,3-GalT
was inactivated in ancestral Old World primates
approximately 20-28 million years ago, resulting in the
absence of a-Gal epitopes in humans, apes, and Old
World monkeys today [1,2]. These evolutionary
descendents of Old World primates produce an anti-
body to Gal-a1,3-Gal-containing oligosaccharides
known as anti-Gal. Anti-Gal is the most abundant nat-
ural antibody in humans, and as a result, exposure to a-
Gal epitopes generates a strong immune response [3].
Many current research efforts exploit the human
immune response to a-Gal epitopes. The efficacy of a
vaccine is often determined by uptake of the vaccine by
antigen presenting cells. Uptake can be greatly enhanced
by the presence of an IgG antibody, such as anti-Gal,
bound to its associated antigen. Based on this principle,
several vaccines have been modified with a-Gal epitopes
in an effort to improve vaccine uptake and efficacy. This
strategy was applied to flu and HIV vaccines and was
found to be more effective than the non-modified vac-
cine in animal studies [4,5]. In addition to enhancing
vaccine efficacy, the immunogenicity of a-Gal epitopes
* Correspondence: rchen@chbe.gatech.edu
School of Chemical and Biomolecular Engineering, Georgia Institute of
Technology, 311 Ferst Drive, Atlanta, GA 30332-0100, USA
Ruffing and Chen Microbial Cell Factories 2010, 9:1
http://www.microbialcellfactories.com/content/9/1/1
© 2010 Ruffing and Chen; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.has been applied to improve cancer treatments. Autolo-
gous tumor vaccines with a-Gal epitopes on the tumor
cells and injections of a-Gal-containing glycolipids were
shown to generate an immune response against malig-
nant tumors in mice [6,7]. The promising results of
these a-Gal-based treatments have stimulated the
demand for a-Gal epitope production.
The increasing interest in a-Gal epitopes for various
medical applications necessitates an efficient and eco-
nomical means of synthesizing the oligosaccharide. Tra-
ditional chemical synthesis requires numerous reaction
steps, leading to low overall yields, a high cost, and a
process that is not applicable for large-scale production.
Enzymatic production of a-Gal epitopes can be achieved
in just one step through the use of an a1,3-GalT; how-
ever, enzymatic synthesis requires provision of an
expensive sugar nucleotide, UDP-galactose. To reduce
cost, enzymatic synthesis schemes often employ a UDP-
galactose 4’-epimerase to provide the UDP-galactose
from a less expensive sugar nucleotide, UDP-glucose
[8,9]. As UDP-glucose is still quite expensive, other
enzymatic synthesis schemes have been developed to
regenerate UDP-galactose through the use of additional
enzymes [10,11]. While these synthesis schemes reduce
the cost of sugar nucleotide provision, they require pro-
duction and purification of multiple enzymes, generally
4t o6 ,a n dm a ya l s or e q u i r eo t h e rh i g he n e r g yc o m -
pounds such as PEP which can still lead to high synth-
esis cost.
Alternatively, whole cell biocatalysts can synthesize a-
Gal epitopes in just one step without enzyme purifica-
tion. Different hosts and engineering strategies were
explored by Wang and coworkers for whole-cell Gal-
a1,3-Lac synthesis. An engineered E. coli was con-
structed by overexpressing five enzymes: three enzymes
of the Gal operon (GalK, GalT, GalU) for UDP-galactose
synthesis, a pyruvate kinase for energy production, and
an a1,3-GalT. In this strategy, glucose and catalytic
amounts of other cofactors (ATP, UDPG, and G1P)
were supplied to the engineered E. coli to initiate Gal-
a1,3-Lac synthesis [12]. Alternatively, an engineered
Pichia pastoris expressed a sucrose synthase which
directly converts sucrose and UDP to UDP-glucose with
fructose as co-product. With two additional enzymes
(UDP-glucose 4’-epimerase and a1,3-GalT), the modi-
fied P. pastoris required only sucrose, lactose, a catalytic
amount of UDP, and a few essential nutrients to pro-
duce Gal-a1,3-Lac. The three recombinant enzymes in
P. pastoris constituted an artificial pathway, whose
operation was independent of cellular metabolism [13].
Both the engineered E. coli and P. pastoris were capable
of synthesizing gram-scale amounts of Gal-a1,3-Lac.
One key challenge with whole-cell catalysts is uptake
of the acceptor sugar, lactose, along with the primary
sugar (i.e. sucrose or glucose). In both the engineered E.
coli and P. pastoris biocatalysts, permeabilization was
found to be necessary [12,13]. While effective at improv-
ing lactose uptake, permeabilization also reduces cell
viability and dissipates the proton gradient used for
energy generation. This may not be a problem when cel-
lular metabolism is not required to generate UDP-glu-
cose, such is the case with sucrose synthase, but
otherwise, it is detrimental to both cellular metabolism
and a-Gal epitope synthesis. To avoid permeabilization,
an E. coli biocatalyst was engineered to synthesize the
acceptor sugar in vivo. Expressing a chitin oligosacchar-
ide synthase (NodC) and several glycosyltransferases, the
recombinant E. coli produced a heptasaccharide a-Gal
epitope without permeabilization of the cell membrane
[14]. While this method avoids the complications
imposed by multiple sugar uptake, the diversion of cell
resources for in vivo substrate synthesis may hinder a-
Gal epitope production.
We have previously demonstrated that Agrobacterium
sp. strain ATCC 31749 is a good host for oligosacchar-
ide production through the synthesis of b1,4-Gal disac-
charides [15]. ATCC 31749 naturally produces high
amounts of a b1,3-glucan polysaccharide known as cur-
dlan. High curdlan production in ATCC 31749 implies
an efficient mechanism for regeneration of the requisite
sugar nucleotide, UDP-glucose. In our previous work,
ATCC 31749 was engineered to convert the UDP-glu-
cose regeneration system into a UDP-galactose regen-
eration system. This current study utilizes the efficient
UDP-galactose production for synthesis of the medi-
cally-relevant a-Gal epitope, Gal-a1,3-Lac. Instead of
using permeabilization or in vivo substrate synthesis, an
alternative strategy is employed to address insufficient
uptake of the substrate sugar, lactose. A lactose per-
mease (LacY) from E. coli is introduced in the Agrobac-
terium host to facilitate lactose transport across the cell
membrane. In addition, sugar nucleotide availability is
improved by eliminating curdlan production, a compet-
ing pathway for utilization of UDP-glucose (Figure 1).
Results
a-Gal epitope synthesis using ATCC 31749/pBQET
ATCC 31749 naturally produces high amounts of cur-
dlan polysaccharide, suggesting an abundant supply of
the sugar nucleotide precursor, UDP-glucose. In order
to utilize UDP-glucose for synthesis of Gal-a1,3-Lac,
two additional enzymes are required: a UDP-galactose
4’-epimerase and an a1,3-galactosyltransferase (Figure
1). In previous work, we demonstrated that the expres-
sion of a galE:lgtB fusion gene in ATCC 31749 can effi-
ciently produce b1,4-Gal oligosaccharides [15]. Adopting
a similar strategy for a-Gal epitope synthesis, a galE:
a1,3-galT fusion gene was constructed using a UDP-
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cated bovine a1,3-galactosyltransferase (a1,3-galT)
(Figure 2A). Inserting the fusion gene into the Agrobac-
terium expression vector, pBQ, yielded pBQET, which
was transformed into ATCC 31749 for synthesis of the
a-Gal epitope. Successful expression of the GalE:a1,3-
GalT fusion enzyme was confirmed with an enzyme
activity assay using ATCC 31749/pBQET. Concentra-
tions of IPTG ranging from 0 to 1 mM were investi-
gated to maximize activity of the fusion enzyme in the
ATCC 31749 host. From 0 to 0.5 mM IPTG, the fusion
enzyme activity increased with increasing IPTG concen-
tration and reached a plateau from 0.5 to 1 mM IPTG
(Table 1). A concentration of 1 mM IPTG was selected
for all subsequent a-Gal epitope synthesis reactions.
The engineered Agrobacterium, ATCC 31749/pBQET,
was utilized for small-scale a-Gal epitope synthesis. The
synthesis process includes two phases. In the first phase,
the engineered Agrobacterium is grown and induced.
After recombinant protein production, the cells are
transferred to a nitrogen-limited minimal media for
synthesis of Gal-a1,3-Lac. Nitrogen-limited conditions
are employed for a-Gal epitope synthesis as curdlan
production, and hence UDP-glucose production, is acti-
vated by this environmental signal. In the a-Gal epitope
synthesis reaction, the engineered strain synthesized
0.39 g/L of the desired product, Gal-a1,3-Lac (Figure 3).
While this result confirms the successful engineering of
ATCC 31749 for a-Gal epitope synthesis, the concentra-
tion of Gal-a1,3-Lac produced is lower than expected.
In our previous work, the engineered Agrobacterium
s y n t h e s i z e du pt o7 . 5g / Lo fb1,4-Gal oligosaccharides,
nearly 20-fold greater than the amount of Gal-a1,3-Lac
produced by ATCC 31749/pBQET [15]. Since ATCC
31749 has the potential to produce much higher levels
of the a-Gal epitope, additional metabolic engineering
strategies were investigated, focusing mainly on
increased acceptor uptake and UDP-glucose availability.
Increased uptake of the acceptor, lactose
A major challenge of whole-cell synthesis is the efficient
transport of reactants across the cell membrane. This
task is particularly difficult for oligosaccharide synthesis
reactions such as a-Gal epitope synthesis. The synthesis
reaction requires uptake of two sugars: the acceptor
sugar (lactose) and a carbon source for production of
the sugar nucleotide and cellular energy (sucrose)
Figure 1 Metabolic pathway for Gal-a1,3-Lac synthesis. Metabolic pathways of ATCC 31749 for Gal-a1,3-Lac synthesis. Cofactors are shown
in bold and enzymes are in bold italics. The double dashed lines indicate the cell membrane, and the dashed arrows represent transport
reactions.
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often prohibited by catabolite repression systems which
allow for uptake of only a preferred carbon source [16].
Nominal uptake of the acceptor, lactose, was suspected
to limit synthesis of the a-Gal epitope in ATCC 31749/
pBQET. Measurement of lactose uptake by ATCC
31749 supported this hypothesis, as the rate of lactose
consumption was more than 45-fold lower than the rate
of sucrose consumption. To confirm that lactose is lim-
iting for Gal-a1,3-Lac synthesis, the extracellular con-
centration of lactose was increased from 25 g/L to 50 g/
L in an effort to increase the intracellular lactose con-
centration by means of diffusion. The higher lactose
concentration led to a 28% increase in Gal-a1,3-Lac
synthesis. An estimate of the intracellular lactose con-
centration indicates that roughly 1 mM of lactose is pre-
sent intracellularly, which is more than 8-fold lower
than the reported Km for the GalE:LgtB fusion enzyme
(Km = 8.5 mM) [17]. These results indicate that lactose
availability may limit a-Gal epitope synthesis.
While doubling the concentration of lactose was suc-
cessful at increasing a-Gal epitope production, diffu-
sion-mediated transport across the cell membrane is
limited, requiring a large increase in lactose concentra-
tion to bring about a small improvement in synthesis. In
this work, an alternative strategy is explored: introdu-
cing a heterologous lactose transporter to increase the
availability of intracellular lactose. A lactose permease
gene (lacY)f r o ma nE. coli K12 strain was expressed
along with the fusion enzyme in the engineered Agro-
bacterium (Figure 2B). LacY is a lactose/proton sympor-
ter that transports lactose across the cytoplasmic
membrane [18]. As expression of a transmembrane pro-
tein is generally not as straightforward as other soluble
proteins, additional steps were taken to provide evidence
of successful expression of lacY.T oa n a l y z et h ee x p r e s -
sion and activity of LacY in the engineered Agrobacter-
ium, uptake of lactose by ATCC 31749/pBQETY was
compared to the lactose uptake of ATCC 31749/pBQET
through analysis of residual lactose concentration in the
extracellular medium. Ther a t eo fl a c t o s eu p t a k ei n
ATCC 31749/pBQETY was approximately 50% greater
than that of ATCC 31749/pBQET, indicating successful
expression and activity of LacY. This measurement relies
on extracellular lactose measurement, however, which
assumes that decreasing lactose concentration is due
solely to uptake by the cell, with no degradation of lac-
tose in the extracellular medium. To confirm that LacY
expression does indeed enhance lactose uptake, the
amount of intracellular lactose was directly measured
throughout the time course of the a-Gal synthesis reac-
tion. These measurements show a 60 to 110% increase
in intracellular lactose concentration for ATCC 31749/
pBQETY compared to ATCC 31749/pBQET. Taken
Figure 2 Plasmids constructed in this study.A :p B Q E T ,
containing the galE:a1,3-galT fusion enzyme for Gal-a1,3-Lac
synthesis; B: pBQETY, containing the galE:a1,3-galT fusion enzyme
and lacY for Gal-a1,3-Lac synthesis and lactose transport; C:
pBScrdShG, containing homologous regions of crdS interrupted by a
gentamicin resistance cassette for crdS knockout.
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LacY and functional insertion of the protein into the
cytoplasmic membrane.
ATCC 31749/pBQETY was employed to determine
the effect of increased lactose availability on a-Gal epi-
tope synthesis. The LacY-expressing strain synthesized
0.65 g/L of Gal-a1,3-Lac, a 67% improvement over
the initial engineered strain, ATCC 31749/pBQET (-
Figure 4). Surprisingly, the activity of the GalE:a1,3-
GalT fusion enzyme was 4.7-fold lower in ATCC 31749/
pBQETY compared to ATCC 31749/pBQET. The lower
activity in the LacY-expressing strain is presumably due
to lower expression of the fusion enzyme. Unlike ATCC
31749/pBQET, the expression exhibited weak depen-
dence on IPTG concentration (Table 1). To determine if
the lower fusion enzyme activity of ATCC 31749/
pBQETY restricts Gal-a1,3-Lac production, 0.05 mM of
IPTG was used for a-Gal epitope synthesis, as both
ATCC 31749/pBQET and ATCC 31749/pBQETY have
similar fusion enzyme activities at this IPTG concentra-
tion. The amount of Gal-a1,3-Lac synthesized by the
LacY-expressing strain was similar to that produced
with 1 mM IPTG; this was expected as the enzyme
activity levels are very similar at both IPTG concentra-
tions. Unexpectedly, the amount of Gal-a1,3-Lac pro-
duced by ATCC 31749/pBQET was similar for both
0.05 mM and 1 mM IPTG despite over a 5-fold reduc-
tion in fusion enzyme activity (Table 1). This suggests
that the activity of the fusion enzyme is not a limiting
factor in Gal-a1,3-Lac synthesis in the wild type
background.
Curdlan synthase knockout for improved UDP-glucose
availability
In addition to limitations imposed by low acceptor (lac-
tose) availability, the amount of the sugar nucleotide,
UDP-glucose, may also restrict a-Gal epitope synthesis
by the GalE:a1,3-GalT fusion enzyme. Under the nitro-
gen-limited conditions of the synthesis reaction, produc-
tion of the a-Gal epitope competes with curdlan
synthesis for the available UDP-glucose (Figure 1). To
determine if UDP-glucose availability limits Gal-a1,3-
Lac production, rifampicin was added to the synthesis
reaction to prevent curdlan production. Since curdlan is
only produced under nitrogen-limitation [19], it is sus-
pected that the curdlan synthesis operon is only tran-
scribed after exhaustion of the nitrogen source.
Therefore, rifampicin, a transcription inhibitor, should
Table 1 GalE:a1,3-GalT fusion enzyme activity
†
Strain IPTG
(mM)
Enzyme Activity
[μmol/(min*L)]
ATCC 31749/pBQET 0 1.2 ± 0.76
0.05 10.7 ± 1.1
0.1 28.0 ± 0.52
0.5 53.4 ± 16.3
1 54.1 ± 5.3
ATCC 31749/pBQETY 0 6.4 ± 0.96
0.05 13.2 ± 0.058
0.1 15.6 ± 1.6
0.5 14.3 ± 0.72
1 11.6 ± 1.2
ATCC 31749ΔcrdS/pBQET 1 38.2 ± 1.7
ATCC 31749ΔcrdS/pBQETY 1 12.6 ± 0.79
†Enzyme activity of GalE:a1,3-GalT fusion enzyme with varying IPTG
concentration. Data are reported as averages of at least two independent
experiments with the associated standard deviation serving as an estimation
of error.
Figure 3 Gal-a1,3-Lac synthesis by ATCC 31749/pBQET. Synthesis of Gal-a1,3-Lac by ATCC 31749/pBQ (control) and ATCC 31749/pBQET.
Data points are averages of three independent experiments with the standard deviation indicated by error bars.
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dlan synthesis during the production of Gal-a1,3-Lac.
The addition of rifampicin led to a 37% increase in Gal-
a1,3-Lac synthesis in ATCC 31749/pBQETY (Figure 4),
indicating that UDP-glucose availability may limit a-Gal
epitope production.
Curdlan, a b1,3-glucan polysaccharide, is not known
to perform any essential or beneficial function for
ATCC 31749. Therefore, by eliminating curdlan produc-
tion, the amount of UDP-glucose available for a-Gal
epitope synthesis will be increased without any detri-
mental impact on the cell. The gene responsible for the
transfer of glucose from UDP-glucose to the growing
curdlan polymer chain was previously determined to be
curdlan synthase, crdS [20]. CrdS has been characterized
and the nucleotide sequence reported, providing the
necessary information required for gene knockout.
This is the first reported attempt at gene knockout in
Agrobacterium sp. strain ATCC 31749; however, suc-
cessful gene knockout has been reported for a related
organism, Agrobacterium tumefaciens. Gene knockout in
A. tumefaciens employed the standard method of inser-
tional mutagenesis via homologous recombination of a
disruption cassette [21]. To determine an effective anti-
biotic resistance cassette for gene knockout, ATCC
31749 was tested for resistance against several antibio-
tics. Two antibiotics, gentamicin and tetracycline, were
found to be effective at preventing ATCC 31749 growth
at concentrations greater than 50 μg/mL. Since the gen-
ome of A. tumefaciens contains several tetracycline
resistance genes, gentamicin was selected for the anti-
biotic resistance cassette in the crdS knockout plasmid.
Sequences homologous to the 5’ and 3’ ends of crdS
(500 bp) were added to each side of the gentamicin
resistance cassette to allow for homologous recombina-
tion. The resulting fragment was inserted into the
pBluescript II (KS
-)p h a g e m i dt og i v et h ecrdS knockout
plasmid, pBScrdShG (Figure 2C). After transformation
of the crdS knockout plasmid into ATCC 31749, genta-
micin-resistant colonies were screened using PCR for
the presence of a 2236 kb fragment containing the inter-
rupted crdS with gentamicin resistance cassette and the
absence of the 1965 kb fragment corresponding to the
intact crdS. A functional screening was also performed
to confirm successful disruption of crdS, using aniline
blue staining to detect curdlan production. The aniline
blue dye binds to b1,3-glucan linkages in curdlan and
produces a bright blue color [22]. In Figure 5, two can-
didate crdS mutants are compared to the wild type
ATCC 31749 strain and a curdlan-deficient mutant pro-
duced via NTG mutagenesis, LTU265. The two crdS
mutants show only a faint blue color, similar to
LTU265, indicating curdlan synthesis was drastically
reduced. As additional evidence for successful crdS
knockout, ATCC 31749ΔcrdS was tested for the forma-
tion of curdlan gel. Heating an aqueous curdlan solution
above 80°C and cooling will lead to the formation of a
curdlan gel [23]. The crdS mutant strain was cultivated
in nitrogen-limited media to initiate curdlan production,
yet the mutant did not form any visible curdlan gel after
the requisite heating and cooling (data not shown). The
cell growth profile for ATCC 31749ΔcrdS in LB media
showed no deviation from the wild-type strain, indicat-
ing that the crdS knockout did not affect cell growth.
Since curdlan is not produced during cell growth, but
rather, under nitrogen-limited conditions, the cell viabi-
lity of ATCC 31749ΔcrdS was studied in minimal, nitro-
gen-free media. The cell viability of the crdS mutant
under curdlan-producing conditions showed no signifi-
cant difference from the wild-type strain (data not
shown). Therefore, curdlan production does not appear
to contribute to cell survival under nitrogen-limited
conditions and should not have a detrimental effect on
a-Gal epitope synthesis.
To determine the effect of the curdlan synthase
knockout on a-Gal epitope synthesis, ATCC
31749ΔcrdS was transformed with pBQET and
pBQETY. ATCC 31749ΔcrdS/pBQETY produced 0.96
g/L of Gal-a1,3-Lac (Figure 6), a concentration similar
to that achieved with the addition of rifampicin (Figure
4). On the other hand, ATCC 31749ΔcrdS/pBQET
synthesized only 0.40 g/L of the a-Gal epitope, indicat-
ing that synthesis remains limited by lactose availability.
Overall, both lactose and UDP-glucose availability con-
tributed to the low levels of Gal-a1,3-Lac produced by
the initial engineered strain, ATCC 31749/pBQET. The
construction of ATCC 31749ΔcrdS/pBQETY, with
increased levels of intracellular lactose and UDP-
Figure 4 Comparison of Gal-a1,3-Lac synthesis by ATCC 31749/
pBQET and ATCC 31749/pBQETY. Synthesis of Gal-a1,3-Lac after
150 hours by ATCC 31749/pBQET and ATCC 31749/pBQETY without
and with rifampicin. Data are averages of three independent
experiments with the standard deviation indicated by error bars.
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host for production of the a-Gal epitope. Requiring only
a carbon source, the acceptor sugar, and a few essential
nutrients (a phosphate source, buffer, and metal cofac-
tors), the engineered Agrobacterium is capable of produ-
cing gram-scale quantities of the a-Gal epitope for
medical research and applications.
Conclusions and Discussion
The whole-cell biocatalysts developed in this study pro-
vide a basis for an efficient and cost-effective means for
large-scale production of the Gal-a1,3-Lac epitope.
Enzymatic and whole-cell methods developed for a-Gal
epitope synthesis face many obstacles including (1) low
synthesis levels, (2) inefficient substrate transport across
the cell membrane, and (3) expensive cofactors. This
work addresses all three of these issues. Host selection
is a critical factor in determining product synthesis
levels. To provide an adequate host for synthesis of the
oligosaccharide, Gal-a1,3-Lac, a polysaccharide-produ-
cing microorganism was selected, Agrobacterium sp.
ATCC 31749. This microorganism can produce up to
93 g/L of curdlan polysaccharide [24], demonstrating a
natural proclivity for synthesizing the sugar nucleotide
precursor, UDP-glucose. With ATCC 31749 as host,
gram-scale quantities of Gal-a1 , 3 - L a cw e r ep r o d u c e d ,
demonstrating an advantage over traditional hosts such
as E. coli. Insufficient uptake of substrate and acceptor
sugars is yet another obstacle in whole-cell oligosacchar-
ide synthesis. To enhance sugar uptake, other strategies
have used permeabilization techniques to weaken the
cell membrane or have expressed additional enzymes to
synthesize the acceptor sugar in vivo [12-14]. In this
work, a lactose permease was introduced into the
Figure 5 Aniline blue staining of curdlan. Aniline blue staining of curdlan production in wild-type and crdS mutant strains. A: ATCC 31749; B:
ATCC 31749ΔcrdS colony 8; C: LTU265; D: ATCC 31749ΔcrdS colony 14.
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acceptor, lactose. This strategy increased lactose uptake
without the undesirable consequences of cell permeabili-
zation techniques, leading to a 67% improvement in
Gal-a1,3-Lac synthesis. The LacY-expressing Agrobac-
terium may also be used to synthesize other lactose-con-
taining oligosaccharides such as Globo-H, the major
component of a vaccine for metastatic breast cancer
[25]. Lastly, expensive cofactors are often added to
enhance production of the sugar nucleotide, including
UDP, ATP, PEP, or even UDP-glucose itself. By deleting
the gene responsible for curdlan synthesis, the efficient
UDP-glucose synthesis pathway of the Agrobacterium
host was exploited for a-Gal epitope synthesis, negating
a need for expensive cofactors. Without the require-
ments of cell permeabilization or cofactors, the engi-
neered Agrobacterium developed in this work is a
suitable biocatalyst for large-scale production of the a-
Gal epitope, and with only slight modification, it may be
utilized for the production of other medically-relevant
oligosaccharides.
While the results clearly show that the metabolic engi-
neering strategies of lacY expression and crdS knockout
are effective in addressing the two respective limitations,
these efforts resulted in only moderate improvements in
a-Gal epitope synthesis. The highest product concentra-
tion was about 1 g/L with shaker flask cultivation, far
below the theoretical potential of 270 g/L (estimated
from reported levels of curdlan synthesis in Agrobacter-
ium sp.). One reason for the lower than expected
improvement is that LacY expression negatively
impacted expression of the fusion enzyme. As shown in
Table 1, the addition of lacY to pBQET leads to nearly
a 5-fold reduction in GalE:a1,3-GalT fusion enzyme
activity. In the future, chromosomal integration of lacY
may be considered to improve lactose uptake while
maintaining the high fusion enzyme activity of the
pBQET strain. The use of shaker flask cultivation may
also contribute to the low level of Gal-a1,3-Lac synth-
esis. Other reported methods of whole-cell a-Gal epi-
tope synthesis utilize fermenters for either high cell
density growth or both growth and the epitope synthesis
reaction [12-14]. Large-scale fermentation may be parti-
cularly beneficial with the engineered Agrobacterium as
high curdlan synthesis requires high levels of dissolved
oxygen and pH control at pH 5.5 [26,27]. Under these
conditions, the engineered crdS mutant should produce
high levels of UDP-glucose for Gal-a1,3-Lac synthesis.
Unfortunately, initial fermentation attempts with the
engineered Agrobacterium were unsuccessful due to the
low recombinant protein production. Chromosomal
integration of the galE:a1,3galT fusion enzyme and
expression using a natural host promoter may overcome
the limited recombinant protein production to allow
large-scale fermentation. The reasons for only modest
improvement from crdS knockout are not clear to us at
this point due to limited knowledge about the regulation
of curdlan synthesis. Recently, we sequenced the gen-
ome of ATCC 31749 and a transcriptome analysis is
being conducted. These efforts will lead to a better
understanding of the regulation mechanism governing
curdlan synthesis and its precursor, UDP-glucose. In
turn, this knowledge will allow metabolic engineers to
formulate better strategies for improving synthesis of a-
Gal epitopes and other oligosaccharides using ATCC
31749 as host.
Methods
Materials
The chemicals used in this study were obtained from
Sigma-Aldrich (lactose, K2HPO4·3H2O, and
MnCl2·4H2O); Acros organics (aniline blue); V-labs, Inc.
(Gal-a1,3-Gal-b1,4-Glc); and Fisher (all other
chemicals).
Bacterial strains and plasmids
The bacterial strains and plasmids used in this study are
described in Table 2.
Construction of pBQET and pBQETY for a-Gal epitope
synthesis
A fusion enzyme containing the E. coli UDP-galactose 4’-
epimerase (galE) and truncated bovine a1,3-galactosyl-
transferase (a1,3-galT) was constructed and inserted into
the Agrobacterium e x p r e s s i o nv e c t o r ,p B Q ,t of o r m
pBQET for a-Gal epitope synthesis. The truncated
bovine a1,3-galT was amplified from pET15b-aGalT
[11]. The 5’ primer for a1,3-galT (5’-TCGGATCCATG-
GAAAGCAAGCTTAAGCTATC-3’)c o n t a i n saBamHI
site (in bold italics) and a start codon (underlined). The
Figure 6 Gal-a1,3-Lac synthesis by the engineered crdS
mutants. Synthesis of Gal-a1,3-Lac by ATCC 31749ΔcrdS/pBQET and
ATCC 31749ΔcrdS/pBQETY. Data points are averages of three
independent experiments with the standard deviation indicated by
error bars.
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TATTTCTAACCACATT-3’)c o n t a i n saSacI site (in
bold italics) and a stop codon (underlined). The amplified
a1,3-galT was inserted into the pGEM-T easy vector to
form pT-a1,3-galT. The a1,3-galT fragment, obtained by
double digestion with BamHI and SacI, was inserted into
the respective restriction sites of the pT-GalE plasmid
containing galE with a linker sequence [15]. Successful
ligation of the a1,3-galT fragment to the digested pT-
GalE yielded pTET, containing the galE:a1,3-galT fusion
gene for a-Gal epitope synthesis. The fusion gene frag-
ment, obtained from BglII and SacI digestions, was fused
to the BamHI and SacI sites of pBQ. The resulting plas-
mid, pBQET, is shown in Figure 2A.
The lactose permease gene (lacY) was cloned from the
genomic DNA of E. coli K12 strain JM109. The 5’ pri-
mer for lacY (5’-ACGAGCTCAAAGAGGAGAAAT
TAACTATGTACTATTTAAAAAACACAAAC-3’)c o n -
tains a SacI site (in bold italics), a ribosome binding site
(underlined), and a start codon (in bold and underlined).
The 3’ primer (5’-GTCTCGAGTTAAGCGACTTCATT-
CACCTG-3’)c o n t a i n sa nXhoI site (in bold italics) and
stop codon (underlined). The amplified lacY fragment
was inserted into the pGEM-T easy vector, yielding pT-
LacY. The lacY fragment, obtained by SacI and XhoI
digestions, was ligated to the SacI and SalI sites of
pBQET to form pBQETY (Figure 2B).
Gene knockout of curdlan synthase (crdS) in ATCC 31749
The knockout plasmid for gene knockout of the curdlan
synthase gene, crdS, was constructed using a gentamycin
resistance cassette flanked on each side by 500 bp of
homology to the curdlan synthase gene. The 5’ primer for
crdS amplification (5’-CGGA GCTCATGTATTT-
CAGTGCTGAAGG-3’)c o n t a i n saSacI site (in bold ita-
lics) and the start codon for crdS (underlined). The 3’
primer for crdS amplification (5’-CCGGTACCTCACCC-
GAATGCCCGTGC-3’) contains a KpnI site (in bold ita-
lics) and crdS stop codon (underlined). The amplified crdS
gene was inserted into the pGEM-T easy vector to pro-
duce pT-crdS. Using pT-crdS as template, the pGEM-T
easy vector along with 500 bp of homology at the 5’ end of
crdS and 500 bp of homology at the 3’ end of crdS were
amplified using phosphorylated primers. The 5’ primer (5’-
pGGCCGAATTCTCGCAATAGGTT CTTACCTC-3’)
contains an EcoRI site (in bold italics) while the 3’ primer
(5’-pGGCAAGCTTTTCGTGACCC TGTCTTCGGC-3’)
Table 2 Bacterial strains and plasmids
Strains or plasmids Description Source
ATCC 31749 Curdlan-producing Agrobacterium sp. ATCC
LTU265 ATCC 31749 locus II mutant with decreased curdlan production B.A. Stone
V.A. Stanisich
JM109 E. coli K12 strain used for lacY cloning Promega
ATCC 31749ΔcrdS ATCC 31749 with interrupted curdlan synthase gene (crdS) This study
pGEM-T easy Vector used for gene cloning Promega
pBQ Broad-host-range expression vector constructed for gene expression in ATCC 31749 [15]
pET15b-aGalT Plasmid containing truncated bovine a1,3-galactosyltransferase gene [11]
pT-a1,3-galT pGEM-T easy vector containing truncated bovine a1,3-galactosyltransferase with BamHI and
SacI restriction sites
This study
pT-GalE Plasmid containing UDP-galactose 4’-epimerase (galE) from E. coli with a short linker sequence
for fusion enzyme construction
[15]
pTET pGEM-T easy vector containing the gale:a1,3galT fusion gene This study
pBQET Plasmid for GalE:a1,3GalT fusion enzyme expression in ATCC 31749 and ATCC 31749ΔcrdS This study
pT-lacY pGEM-T easy vector containing lactose permease gene (lacY) from JM109 with SacI and XhoI
restriction sites
This study
pBQETY Plasmid for expression of GalE:a1,3GalT fusion enzyme and E. coli lactose permease (LacY) in
ATCC 31749 and ATCC 31749ΔcrdS
This study
pT-crdS pGEM-T easy vector containing curdlan synthase gene (crdS) with SacI and KpnI restriction sites This study
pT-crdSh pGEM-T easy vector containing two 500 bp regions of homology to crdS with SacI/KpnI and
EcoRI/HindIII restriction sites
This study
pBluescript II (KS
-) Phagemid for gene knockout in ATCC 31749 Stratagene
pBScrdSh pBluescript II (KS
-) containing two 500 bp regions of homology to crdS with EcoRI and HindIII
restriction sites
This study
pYanni2 Plasmid containing a gentamicin resistance cassette [28]
pT-GmR pGEM-T easy vector containing gentamicin resistance cassette with EcoRI and HindIII restriction
sites
This study
pBScrdShG crdS knockout plasmid; pBluescript II (KS
-) containing a gentamicin resistance cassette flanked
by two 500 bp regions of homology to crdS
This study
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with homologous regions of crdS was self-ligated to form
pT-crdSh. pT-crdSh was digested using SacI and KpnI,
and the resulting fragment containing crdS homology
(crdSh) was inserted into the corresponding restriction
sites of pBluescriptII (KS
-), generating the plasmid
pBScrdSh. The gentamicin resistance gene (Gm
R), along
with its promoter and transcription terminator, was ampli-
fied from pYanni2 [28]. The 5’ primer for Gm
R amplifica-
tion (5’-CCGAATTCGTCTAGTGAGTAGTG GGTAC-
3’)c o n t a i n sa nEcoRI site (in bold italics), and the 3’ pri-
mer (5’-CGAAGCTT GCTTGCAAACAAAAAAAC-
CACC-3’) contains a HindIII site. The amplified fragment
containing Gm
R was inserted into the pGEM-T easy vec-
tor, forming pT-GmR. pT-GmR was digested using EcoRI
and HindIII, and the fragment containing Gm
R was
inserted into the corresponding restriction sites in
pBScrdSh to form pBScrdShG (Figure 2C). The knockout
plasmid, pBScrdShG, was transformed into ATCC 31749
using electroporation, followed by a 5 hour cultivation
without antibiotics, and growth on LB/agar plates contain-
ing 50 μg/mL of gentamicin. The KO candidate colonies
were grown four times in LB media at 30°C and 250 rpm
to cure pBScrdShG.
Cell growth and GalE:a1,3GalT enzyme activity assay
ATCC 31749/pBQET, ATCC 31749/pBQETY, ATCC
31749ΔcrdS/pBQET, and ATCC 31749ΔcrdS/pBQETY
inoculums were prepared at 30°C and 250 rpm in a cul-
ture tube with 4 mL of LB media containing 100 μg/mL
of kanamycin and 100 μg/mL of ampicillin. The inocu-
lums were diluted 500× and grown in 150 mL of freshly
prepared LB media supplemented with antibiotics until
an OD600 of 0.3 - 0.4 was reached, upon which IPTG
was added to a final concentration of 1 mM. After
IPTG addition, the cell culture was incubated at 30°C
and 250 rpm for another 6 hours.
For the enzyme activity assay, the induced cells were
collected by centrifugation at 5,000 × g and 4°C for 2
min. The cell pellet was resuspended in a buffer contain-
ing 25 mM Tris-HCl (pH 7.5), 10 mM MnCl2,1 0 0m M
NaCl, and 0.25% Triton X to a final cell concentration of
20% wet wt/v. Using a Branson Mode 250 Sonifer, the
mixture was sonicated 6 times for 15 second intervals
with 1 min rest on ice. The lysates were centrifuged for 2
min at 10,000 × g at 4°C, and 50 μL of supernatant was
added to the substrate mixture for the enzyme activity
assay. The substrate mixture consists of 20 mM lactose
(10 mM final concentration) and 8 mM of UDP-glucose
(4 mM final concentration) in the enzyme activity buffer
described previously. The assay was conducted at 30°C
for 40 min followed by 10 min at 97°C to stop the reac-
tion. The deactivated enzyme mixture was diluted 50×,
and the Gal-a1,3-Lac product was analyzed using the
protocol detailed below (Carbohydrate analysis).
Cell viability
ATCC 31749 and ATCC 31749ΔcrdS inoculums were
prepared at 30°C and 250 rpm in a culture tube with 4
mL of LB media containing 10 μg/mL of gentamicin for
the crdS mutant. The inoculums were diluted 1000×
and grown in 150 mL of freshly prepared LB media,
supplemented with antibiotics for ATCC 31749ΔcrdS.
After 12 hours of growth in LB, the cells were collected
by centrifugation at 3000 × g for 10 min at 4°C. The
cell pellets were washed with 10% glycerol and then
resuspended in nitrogen-free media. The nitrogen-free
media consisted of 70 g/L sucrose, 1 g/L K2HPO4·3H2O,
5g / LM g S O 4·7H2O, 5 g/L sodium citrate, 1 g/L
MnCl2·4H2O, and 50 mM Tris-HCl (pH 7.5). The cells
were cultivated in nitrogen-free media at 30°C and 250
rpm in a biological shaker for 72 hours. Samples were
taken at intervals of 12 hours and diluted using sterile
LB media. The diluted cultures were spread on LB/agar
plates, and colony forming units (cfu’s) were counted as
a measure of cell viability.
a-Gal epitope synthesis
The induced cells were prepared as described above
(Cell growth and GalE:a1,3-GalT enzyme activity assay).
The cells were then collected by centrifugation for 10
min at 3,000 × g and 4°C. The cell pellets were washed
once with sterile 10% glycerol, and then resuspended in
the reaction media. The reaction media contained 50 g/
L sucrose, 25 g/L lactose, 1 g/L K2HPO4·3H2O, 5 g/L
MgSO4·7H2O, 5 g/L sodium citrate, 1 g/L MnCl2·4H2O,
and 50 mM Tris-HCl (pH 7.5). The final cell concentra-
tion was 10% wet wt/v, and the reaction vessel was a 50
mL Erlenmeyer flask. The reaction vessel was placed in
a biological shaker at 30°C and 250 rpm. Samples were
centrifuged for 3 min at 13,200 rpm. The supernatant
was heated in boiling water for 10 min and then centri-
fuged again at 13,200 rpm for 3 min. The supernatant
was appropriately diluted and analyzed as described in
Carbohydrate analysis.
Analytical techniques
SDS-PAGE
SDS-PAGE was used to confirm the successful expres-
sion of the GalE:a1,3-GalT fusion enzyme. JM109/
pBQET was inoculated in 4 mL of LB media containing
100 μg/mL of kanamycin and 100 μg/mL of ampicillin.
After overnight growth at 37°C with 250 rpm, 3 mL of
the inoculum was transferred to 150 mL of LB media
with antibiotics and grown at 37°C with 250 rpm. When
an OD600 of 0.2 - 0.3 was reached, the cultures were
induced with IPTG (final concentration 1 mM). Imme-
diately after the addition of IPTG, the temperature was
shifted to 25°C. After an induction period of 4 hours,
the culture was centrifuged at 3,000 × g and 4°C for 10
min. The cell pellet was washed with 0.4 M NaCl and
collected by centrifugation. A buffer containing 100 mM
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inhibitor cocktail (Sigma-Aldrich) was used to resuspend
the cell pellet to a final concentration of 0.2 g/mL (wet
weight). The cell suspension was sonicated 8 times for
10 second intervals with 1 min rest on ice. Cellular deb-
ris was removed by centrifugation at 3,000 × g and 4°C
for 20 min. The GalE:a1,3-GalT fusion enzyme was pur-
ified from the supernatant using a HIS select HF nickel
affinity gel (Sigma-Aldrich). A 12% Tris-HCl gel (Bio-
Rad) was used for SDS-PAGE to analyze the His-tag
purified and soluble protein fractions.
Carbohydrate analysis
Diluted samples were analyzed using a Dionex BioLC
system with a CarboPac PA20 analytical column. The
Dionex ED50 electrochemical detector measured carbo-
hydrate concentrations through pulsed amperometry
(waveform: t = 0.41 sec, p = -2.00 V; t = 0.42 sec, p =
-2.00 V; t = 0.43 sec, p = 0.60 V; t = 0.44 sec, p = -0.10
V; t = 0.50 sec, p = -0.10 V). Sucrose, lactose, and Gal-
a1,3-Lac concentrations were determined using calibra-
tion curves prepared from standards. The mobile phase
consisted of degassed 200 mM sodium hydroxide (A)
and 18 MΩ-cm water (B), pressurized with inert gas
(He) at a flow rate of 0.5 mL/min. The following linear
gradient was used for sucrose and lactose detection: t =
0 min, 5:95 (A:B); t = 5 min, 5:95; t = 10 min, 20:80; t =
25 min, 20:80; t = 25 min, 100:0; t = 40 min, 100:0; t =
40 min, 5:95; t = 55 min, 5:95. The linear gradient for
Gal-a1,3-Lac detection entails the following steps: t = 0
min, 30:70 (A:B); t = 35 min, 30:70; t = 35 min, 100:0; t
= 50 min, 100:0; t = 50 min, 30:70; t = 60 min, 30:70.
Intracellular lactose measurement
ATCC 31749/pBQET and ATCC 31749/pBQETY were
prepared as described above (a-Gal epitope synthesis).
Samples (1 mL) were taken from both reaction vessels
at 34 and 45 hours after the start of the synthesis reac-
tion and centrifuged for 5 min at 5,000 × g and 4°C.
The supernatant was removed and used for analysis of
extracellular lactose and Gal-a1,3-Lac. The cell pellet
was washed with 50 mM of Tris-HCl buffer (pH 7.5)
and centrifuged a total of three times to remove any
residual extracellular lactose. After washing, the cell pel-
let was resuspended in 600 μLo f5 0m MT r i s - H C lb u f -
fer (pH 7.5). The cells were disrupted using sonication
(6 × 10 sec, 1 min rest on ice). Cell debris was removed
by centrifugation, and the supernatant containing the
intracellular lactose was heated for 10 min in boiling
water to denature any proteins. After centrifugation, the
sample was diluted 50× and analyzed as described in
Carbohydrate analysis to determine the amount of lac-
tose in mmol. The intracellular volume was determined
by taking another 1 mL sample and collecting the cell
pellet by centrifugation. The cell pellet was washed with
DI water and centrifuged three times to remove any
residual media. The wet weight of the cell pellet was
measured, and then, the cell pellet was dried in an oven
at 80°C until a constant dry weight was obtained. The
difference in weight between the wet and dry cell pellets
was used to calculate the intracellular volume. The
intracellular lactose concentration was then calculated
using the amount of lactose determined through carbo-
hydrate analysis and the intracellular volume.
Curdlan detection
T h ee l i m i n a t i o no fc u r d l a np r o d u c t i o ni nA T C C
31749ΔcrdS was detected using an aniline blue staining
method [22]. Candidate colonies were streaked on LB/
agar plates containing 0.005% aniline blue. The plates
were incubated for 5 days at 30°C, and the stained cur-
dlan (blue) was detected by visual inspection.
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